Rein Therapeutics Inc. Common Stock (RNTX)

About RNTX

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

10

Website

www.reintx.com/

Fundamentals

1-day range

$0.7621$0.7877

Market cap

$63.77M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-1.78

Dividend yield

—

Beta

1.36

Avg. volume

509.6K

Forecasts

2 analyst ratings

Rein Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• RNTX

  Rein Therapeutics Inc. Common Stock

  $0.7621

  ▼ 2.67%
  Market cap $63.77MP/E —
  $0.694$2.18
• PLRX

  Pliant Therapeutics Inc. Common Stock

  $1.11

  ▼ 3.48%
  Market cap $64.40MP/E —
  $1.02$1.95
• CING

  Cingulate Inc. Common Stock

  $5.32

  ▼ 2.21%
  Market cap $65.06MP/E —
  $3.16$11.89
• MNOV

  Medicinova Inc Common Stock

  $1.44

  ▲ 1.05%
  Market cap $65.46MP/E —
  $1.17$1.96
• ELTX

  Elicio Therapeutics Inc. Common Stock

  $2.86

  ▼ 4.67%
  Market cap $65.84MP/E —
  $2.66$16
• SPRO

  Spero Therapeutics Inc. Common Stock

  $1.2

  ▼ 0.83%
  Market cap $66.59MP/E 4.73
  $1.08$3.08
• ACRV

  Acrivon Therapeutics Inc. Common Stock

  $2.06

  ▼ 4.19%
  Market cap $66.77MP/E —
  $1.27$3.56

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• FDA Grants Rein Therapeutics Fast Track Designation For LTI-03
  benzinga · 8/20/2026

Institutional Ownership

March 31, 2026

Total shares held

11.21M

Total value held

$14.56M

Institutional holders

43